Skip to main content
Skip to main content
SKHHY logo

Sonic Healthcare Limited (SKHHY) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$13.61 +$0.044 (+0.32%) |CouncilBullish Lean · 69 · B+
MCap: $6.73B| P/E Ratio: 15.74| Vol: 706|

P/E 15.74 means the share price is 15.74 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $6.73B is the value of all shares combined. Beta 0.54: the stock has moved about 46% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Sonic Healthcare Limited (SKHHY) trades at $13.61. Sonic Healthcare Limited is a global medical diagnostics company providing laboratory and radiology services. The company operates across multiple countries, including Australia, the United States, and Europe. Market cap: $6.73B, Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026
Sonic Healthcare Limited is a global medical diagnostics company providing laboratory and radiology services. The company operates across multiple countries, including Australia, the United States, and Europe.

Analyst Coverage for SKHHY: SKHHY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SKHHY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the SKHHY film Every key number, told as a short cinematic story — just press play. ~2 min

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Council Score · Weighted Average of 3 Disciplines
Bullish Lean 69/100 · B+

SKHHY: 2/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Favorable read
Simons-style lens (simulated)Jim Simons
Favorable read
Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Favorable read
Moon AI lens (model)
Favorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Sonic Healthcare Limited (SKHHY) Healthcare & Pipeline Overview

CEOJames Pacey Newcombe
Employees42,000
HeadquartersSydney, AU
IPO Year2010

Sonic Healthcare Limited is a global medical diagnostics company providing comprehensive pathology and radiology services to clinicians, hospitals, and community health services. Operating across multiple geographies, including Australia, the United States, and Europe, Sonic Healthcare plays a crucial role in healthcare delivery through its diagnostic capabilities.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for SKHHY?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

With a P/E ratio of 15.74 and a dividend yield of 5.21%, the company demonstrates stable profitability and shareholder returns. A gross margin of 29.6% and a profit margin of 5.2% indicate efficient operations. Key growth catalysts include the increasing demand for diagnostic services and expansion into new geographic markets. However, potential risks include regulatory changes and competition from other diagnostic service providers. The company's beta of 0.54 suggests lower volatility compared to the broader market, making it a potentially stable investment.

Based on FMP financials and quantitative analysis

SKHHY Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $6.73B reflects Sonic Healthcare's significant presence in the medical diagnostics industry.

  • P/E ratio of 15.74 indicates a reasonable valuation relative to earnings.
  • Dividend yield of 5.21% provides a substantial income stream for investors.
  • Gross margin of 29.6% demonstrates the company's ability to manage its cost of goods sold effectively.
  • Beta of 0.54 suggests lower volatility compared to the overall market.

Who Are SKHHY's Competitors?

SKHHY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CNVVF ConvaTec Group Plc $2.91 -2.75% $5.67B
DSRLF DiaSorin S.p.A. $86.00 0.00% $4.25B 529-signal
GNGBY Getinge AB (publ) $24.30 -1.84% $6.62B
MSMKF MatsukiyoCocokara & Co. $14.88 0.00% $5.85B
RDNT RadNet, Inc. $74.28 +4.81% $5.84B 335-pillar
TWST Twist Bioscience Corporation $126.90 +0.04% $7.90B 355-pillar
QGEN Qiagen N.V. $42.13 -0.87% $8.69B 835-pillar
SHC Sotera Health Company $18.26 -0.38% $5.21B 765-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SKHHY's Key Strengths?

Comprehensive range of diagnostic services.

  • Global presence and geographic diversification.
  • Established brand reputation.
  • Extensive network of medical laboratories and imaging centers.

What Are SKHHY's Weaknesses?

Exposure to regulatory changes in multiple countries.

  • Dependence on healthcare provider relationships.
  • Potential for technological obsolescence.
  • Currency risk due to international operations.

What Could Drive SKHHY Stock Higher?

SKHHY catalyst: Increasing demand for diagnostic services due to an aging population and rising prevalence of chronic diseases.

  • Expansion into new geographic markets, particularly in emerging economies.
  • Potential acquisitions of smaller diagnostic service providers to expand market share.
  • Technological advancements in diagnostic technologies, such as molecular diagnostics and personalized medicine.
  • Strategic partnerships with healthcare providers to enhance market access and service delivery.

What Are the Key Risks for SKHHY?

Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.

  • Regulatory changes in multiple countries affecting diagnostic service operations.
  • Economic downturns reducing healthcare spending and diagnostic service demand.
  • Competition from other diagnostic service providers.
  • Data security and privacy breaches compromising patient information.
  • Currency risk due to international operations.

What Are the Growth Opportunities for SKHHY?

  • Expansion into Emerging Markets: Sonic Healthcare has the opportunity to expand its operations into emerging markets with growing healthcare needs. These markets often lack advanced diagnostic infrastructure, presenting a significant opportunity for Sonic Healthcare to establish a presence and capture market share. The timeline for this expansion could be within the next 3-5 years, with a potential market size of several billion dollars.
  • Increased Demand for Diagnostic Services: The increasing prevalence of chronic diseases and an aging global population are driving demand for diagnostic services. Sonic Healthcare is well-positioned to capitalize on this trend by expanding its service offerings and investing in advanced diagnostic technologies. This is an ongoing opportunity with a continuously expanding market size.
  • Technological Advancements in Diagnostics: Advancements in diagnostic technologies, such as molecular diagnostics and personalized medicine, are creating new opportunities for Sonic Healthcare. By investing in these technologies, the company can enhance its service offerings and improve diagnostic accuracy. The timeline for realizing these opportunities is within the next 2-3 years.
  • Strategic Acquisitions: Sonic Healthcare can pursue strategic acquisitions to expand its geographic reach and service offerings. Acquiring smaller diagnostic service providers in key markets can provide access to new customers and technologies. The timeline for potential acquisitions is ongoing, with the market size depending on the specific targets.
  • Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare providers can enhance Sonic Healthcare's market access and service delivery. By forming strategic partnerships, the company can integrate its diagnostic services into the broader healthcare ecosystem. This is an ongoing opportunity with a continuously expanding market size.

What Are SKHHY's Competitive Advantages?

  • Established brand reputation and long-standing relationships with healthcare providers.
  • Extensive network of medical laboratories and imaging centers.
  • Comprehensive range of diagnostic services.
  • Global presence and geographic diversification.

What Does SKHHY Do?

Sonic Healthcare Limited, established in 1934 and headquartered in Sydney, Australia, is a leading international medical diagnostics company. The company provides a wide array of services, including laboratory medicine/pathology and diagnostic imaging/radiology. Its radiology services encompass magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Sonic Healthcare also offers primary care medical services, including general practice, occupational health, remote health, community and home nursing, research programs, health assessment technologies, clinical trials, and chronic disease management. Sonic Healthcare serves a diverse clientele, including clinicians, hospitals, community health services, and patients. With operations spanning Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland, Belgium, and Ireland, the company has established a significant global presence. Its comprehensive service offerings and broad geographic reach position Sonic Healthcare as a key player in the medical diagnostics industry. The company also provides administrative services and facilities to medical practitioners, further integrating its services within the healthcare ecosystem.

What Products and Services Does SKHHY Offer?

  • Provides laboratory medicine/pathology services.
  • Offers diagnostic imaging/radiology services, including MRI, CT, and X-ray.
  • Delivers primary care medical services, including general practice and occupational health.
  • Offers remote health services and community and home nursing.
  • Conducts primary care research programs and clinical trials.
  • Provides health assessment technologies and chronic disease management programs.
  • Offers administrative services and facilities to medical practitioners.

How Does SKHHY Make Money?

  • Generates revenue through fees for diagnostic testing and imaging services.
  • Contracts with hospitals, clinics, and other healthcare providers to provide diagnostic services.
  • Operates a network of medical laboratories and imaging centers.
  • Provides administrative services to medical practitioners for a fee.

What Industry Does SKHHY Operate In?

Sonic Healthcare operates within the medical diagnostics and research industry, a sector characterized by continuous technological advancements and increasing demand for accurate and timely diagnostic information. The industry is driven by factors such as an aging population, the rising prevalence of chronic diseases, and advancements in medical technology. Sonic Healthcare competes with other diagnostic service providers, including CNVVF (Clover Health Investments Corp), CNVVY (Clover Health Investments Corp), DSRLF (DShare Health), GNGBY (Guardant Health Inc), and MSMKF (Medica Holding SA), in a fragmented market. The company's comprehensive service offerings and global presence provide a competitive edge.

Who Are SKHHY's Key Customers?

  • Clinicians who order diagnostic tests for their patients.
  • Hospitals that require diagnostic services for their patients.
  • Community health services that provide diagnostic testing to the public.
  • Patients who directly access diagnostic services.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Medium 45/100

Enough evidence to be useful, with gaps worth knowing about.

  • Scoring coverage unknown
  • Price is current
  • Latest filing 73 days ago
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 52
2026-08-26 52
2026-08-29 52
2026-09-01 52
2026-09-04 52
2026-09-07 52
2026-09-10 52

What changed?

The score has stayed at 52.

Over the same 18 days the stock moved -7.9%.

Sonic Healthcare Limited (SKHHY) Valuation Context

Valued at $6.73B, SKHHY is classified as a mid-cap stock.

SKHHY Revenue & Earnings Trend

In Q4 FY2026, SKHHY generated $5.62B in top-line revenue, marking a sequential increase of 5.7%. The company recorded net income of $350.7M, with diluted EPS of $0.71. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, SKHHY averaged $0.50 in diluted EPS.

Company Profile

Sonic Healthcare Limited operates in the Diagnostics & Research industry within the Healthcare sector. It is headquartered in Sydney, Australia.

ROE 7%

Key Financial Metrics

Return on equity for Sonic Healthcare Limited stands at 7.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.6%, showing how much profit it generates from its asset base. SKHHY trades at a trailing price-to-earnings ratio of 15.74, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 8.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.99 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 6.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9

Financial Health

Sonic Healthcare Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.41 places it in the grey zone, a middle ground that warrants monitoring.

1/8 beats

Earnings Track Record

Sonic Healthcare Limited has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 3.3% below estimates on average.

SKHHY Financials

Fundamental Snapshot

Revenue Growth (FY)
+11.0%
Net Income Growth (FY)
+15.8%
EPS Growth (FY)
+12.1%
Free Cash Flow Growth (FY)
-21.1%
P/E (TTM)
15.74
Return on Equity (TTM)
+7.2%
Current Ratio
1.0
EV/EBITDA (TTM)
7.5

Based on FMP financials and quantitative analysis · FY 2026

Bull Case vs Bear Case

Bull Case

  • Comprehensive range of diagnostic services.
  • Global presence and geographic diversification.
  • Established brand reputation.
  • Extensive network of medical laboratories and imaging centers.

Bear Case

  • Exposure to regulatory changes in multiple countries.
  • Dependence on healthcare provider relationships.
  • Potential for technological obsolescence.
  • Currency risk due to international operations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q4 FY2026 A$5.62B A$351M A$0.71
Q2 FY2026 A$5.31B A$258M A$0.52
Q4 FY2025 A$2.49B A$138M A$0.29
Q2 FY2025 A$4.67B A$237M A$0.49

Q4 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep

Based on FMP financials and quantitative analysis · Reported in AUD

SKHHY Latest News

SKHHY Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SKHHY.

Price Targets

Wall Street price target analysis for SKHHY.

SKHHY MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SKHHY; grades run from A+ (80-100) to F (below 30).

Leadership: James Pacey Newcombe

Managing Director

James Pacey Newcombe is the Managing Director of Sonic Healthcare Limited. His leadership guides the company's strategic direction and operational execution across its global network. However, his current position indicates extensive experience in the healthcare and diagnostics industry.

Track Record: Under James Pacey Newcombe's leadership, Sonic Healthcare Limited manages a workforce of 42,000 employees. Specific milestones and strategic decisions under his tenure are not detailed in the provided data. However, his role as Managing Director suggests a significant influence on the company's growth and performance.

Sonic Healthcare Limited ADR Information Unsponsored

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SKHHY is a Level 1 ADR, meaning it trades over-the-counter (OTC) rather than on a major exchange. This allows U.S. investors to invest in Sonic Healthcare without directly dealing with foreign markets.

  • Home Market Ticker: Australian Securities Exchange (ASX), Australia
  • ADR Level: 1
  • ADR Ratio: 1:1
  • Home Market Ticker: SKHH
Currency Risk: As an ADR, SKHHY is subject to currency risk. The value of the ADR is affected by fluctuations in the exchange rate between the U.S. dollar and the Australian dollar. If the Australian dollar weakens against the U.S. dollar, the value of the ADR may decrease, and vice versa.
Tax Implications: Dividends paid on SKHHY ADRs are subject to foreign dividend withholding tax by the Australian government. The standard withholding tax rate is 30%, but this may be reduced under tax treaties between Australia and the U.S. Investors should consult with a tax advisor to determine their specific tax obligations.
Trading Hours: The Australian Securities Exchange (ASX) operates on different trading hours compared to U.S. markets. The ASX is typically open from 10:00 AM to 4:00 PM Sydney time, which translates to 8:00 PM to 2:00 AM Eastern Time. This means that there is limited overlap between trading hours, which may affect the ability to trade SKHHY ADRs in real-time.

SKHHY OTC Market Information

The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and transparency compared to exchange-listed securities. These companies may not be current in their reporting requirements.

  • OTC Tier: OTC Other
Liquidity: Liquidity for SKHHY on the OTC market is likely to be limited due to its OTC Other tier status. This can result in wider bid-ask spreads and make it difficult to buy or sell large quantities of shares without significantly impacting the price. Investors should be prepared for potential trading difficulties and price volatility.
OTC Risk Factors:
  • Limited financial disclosure due to OTC Other tier status.
  • Potential for fraud or manipulation due to lack of regulatory oversight.
  • Low liquidity and wide bid-ask spreads.
  • Higher price volatility compared to exchange-listed stocks.
  • Risk of delisting or suspension from the OTC market.
Due Diligence Checklist:
  • Verify the company's registration and legal status.
  • Attempt to obtain and review any available financial statements.
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Understand the risks associated with investing in OTC Other stocks.
  • Consult with a financial advisor before investing.
  • Check for any news or regulatory actions related to the company.
Legitimacy Signals:
  • Established operations in multiple countries.
  • Long operating history since 1934.
  • Presence in the healthcare sector, which is subject to regulatory oversight.
  • ADR listing, indicating some level of compliance with U.S. regulations.

What Investors Ask About Sonic Healthcare Limited (SKHHY) — Healthcare

Is SKHHY a good stock?

Stock Expert AI does not rate SKHHY buy, sell or hold. Sonic Healthcare Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What are the main risks for SKHHY?

The main risks for Sonic Healthcare Limited include regulatory changes in the various countries where it operates, potential economic downturns affecting healthcare spending, and competition from other diagnostic service providers.

What are the key factors to evaluate for SKHHY?

Evaluate SKHHY on fundamentals, analyst consensus, and risk factors. P/E: 15.74x vs the S&P 500's ~20-25x. A gross margin of 29.6% and a profit margin of 5.2% indicate efficient operations. Not financial advice.

How frequently does SKHHY data refresh on this page?

SKHHY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven SKHHY's recent stock price performance?

Sonic Healthcare Limited (SKHHY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive range of diagnostic services. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SKHHY overvalued or undervalued right now?

Sonic Healthcare Limited (SKHHY) trades at 15.74x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of SKHHY?

Yes, most major brokerages offer fractional shares of Sonic Healthcare Limited (SKHHY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track SKHHY's earnings and financial reports?

Sonic Healthcare Limited (SKHHY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SKHHY earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may not be exhaustive.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover